CanSino Biologics Inc.
CASBFOTCHealthcare● Active
$3.97
+$0.97(+32.33%)
Market Cap$1.4B
P/E Ratio—
52W High$6.99
52W Low$3
CanSino Biologics Inc. (CASBF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CASBF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.03B | ($0.38B) | ($1.98B) | ($1.18B) | $1.91B |
| Depreciation & Amort. | $0.17B | $0.21B | $0.27B | $0.20B | $0.09B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.01B | $0.01B | $0.01B |
| Change in Working Capital | ($0.16B) | ($0.12B) | ($0.16B) | ($1.48B) | $0.08B |
| Net Cash from Operations | $0.03B | ($0.17B) | ($0.91B) | ($1.89B) | $2.01B |
| Investing Activities | |||||
| Capital Expenditure | ($0.19B) | ($0.46B) | ($0.61B) | ($1.08B) | ($1.20B) |
| Purchases of Investments | ($7.43B) | ($12.93B) | ($8.09B) | ($12.36B) | ($8.48B) |
| Sales of Investments | $8.01B | $13.42B | $8.30B | $12.21B | $7.12B |
| Net Cash from Investing | $0.36B | $0.00B | ($0.45B) | ($1.19B) | ($2.53B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | ($0.01B) | $0.00B | ($0.15B) | $0.00B |
| Dividends Paid | $0.00B | ($0.06B) | ($0.00B) | ($0.19B) | ($0.01B) |
| Debt Issued / Repaid | ($0.70B) | ($0.26B) | $0.07B | $1.27B | $0.99B |
| Net Cash from Financing | ($0.70B) | ($0.33B) | ($0.01B) | $0.85B | $1.56B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.15B) | ($0.63B) | ($1.53B) | ($2.96B) | $0.81B |
| FCF Margin %(computed) | -14.81% | -75.94% | -442.29% | -287.34% | 18.87% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · CNY · B
Explore more CanSino Biologics Inc. data
About CanSino Biologics Inc. (CASBF) Cash Flow Statement
CanSino Biologics Inc. generated operating cash flow of $0.03B and free cash flow of ($0.15B) for 2025 — a FCF margin of -14.81%. Capital expenditure was ($0.19B).
Frequently asked questions
CASBF · 4 questionsCanSino Biologics Inc. generated free cash flow of ($0.15B) for 2025, up 75.6% year-over-year.
CASBF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10